ATE412671T1 - Modifizierter faktor viii - Google Patents
Modifizierter faktor viiiInfo
- Publication number
- ATE412671T1 ATE412671T1 AT03746308T AT03746308T ATE412671T1 AT E412671 T1 ATE412671 T1 AT E412671T1 AT 03746308 T AT03746308 T AT 03746308T AT 03746308 T AT03746308 T AT 03746308T AT E412671 T1 ATE412671 T1 AT E412671T1
- Authority
- AT
- Austria
- Prior art keywords
- factor viii
- fviii
- modified
- modified factor
- immunogenic
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title abstract 3
- 102000001690 Factor VIII Human genes 0.000 abstract 3
- 108010054218 Factor VIII Proteins 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 102000057593 human F8 Human genes 0.000 abstract 1
- 229960000900 human factor viii Drugs 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 102000035118 modified proteins Human genes 0.000 abstract 1
- 108091005573 modified proteins Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02008712 | 2002-04-18 | ||
| EP03006554 | 2003-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE412671T1 true ATE412671T1 (de) | 2008-11-15 |
Family
ID=29252205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03746308T ATE412671T1 (de) | 2002-04-18 | 2003-04-17 | Modifizierter faktor viii |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20050256304A1 (de) |
| EP (1) | EP1495052B9 (de) |
| JP (1) | JP2005538694A (de) |
| KR (1) | KR20040103970A (de) |
| CN (1) | CN1646564A (de) |
| AT (1) | ATE412671T1 (de) |
| AU (1) | AU2003232482A1 (de) |
| BR (1) | BR0308860A (de) |
| CA (1) | CA2482926A1 (de) |
| DE (1) | DE60324406D1 (de) |
| ES (1) | ES2319758T3 (de) |
| MX (1) | MXPA04010061A (de) |
| PL (1) | PL371278A1 (de) |
| RU (1) | RU2004133761A (de) |
| WO (1) | WO2003087161A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1636360A4 (de) | 2003-06-03 | 2006-11-08 | Cell Genesys Inc | Zusammensetzungen und verfahren zur verstärkten expression rekombinanter polypeptide von einem vektor unter verwendung einer peptidspaltstelle |
| US7485291B2 (en) | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| MX350293B (es) | 2004-11-12 | 2017-09-04 | Bayer Healthcare Llc | Modificacion dirigida al sitio del factor viii. |
| WO2006063031A2 (en) | 2004-12-06 | 2006-06-15 | Haplomics | Allelic variants of human factor viii |
| FR2913020B1 (fr) * | 2007-02-23 | 2012-11-23 | Biomethodes | Nouveaux facteurs viii pour le traitement des hemophiles de type a |
| WO2008157776A2 (en) * | 2007-06-21 | 2008-12-24 | Angelica Therapeutics, Inc. | Modified diphtheria toxins |
| GB0723712D0 (en) * | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| GB0801513D0 (en) * | 2008-01-28 | 2008-03-05 | Circassia Ltd | Peptides from factor VIII |
| WO2009110944A1 (en) * | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
| GB0908515D0 (en) * | 2009-05-18 | 2009-06-24 | Apitope Technology Bristol Ltd | Peptide |
| US20130123181A1 (en) * | 2009-11-13 | 2013-05-16 | Kathleen Pratt | Factor VIII T Cell Epitope Variants Having Reduced Immunogenicity |
| WO2011088391A2 (en) * | 2010-01-14 | 2011-07-21 | Haplomics, Inc. | Predicting and reducing alloimmunogenicity of protein therapeutics |
| JP6122780B2 (ja) * | 2010-10-27 | 2017-04-26 | バクスアルタ ゲーエムベーハー | 免疫寛容誘導および免疫診断のためのｆｖｉｉｉペプチド |
| EP2666782A1 (de) * | 2012-05-22 | 2013-11-27 | Imnate Sarl | Gerinnungsfaktor VII mit reduzierter Immunogenität |
| US10272163B2 (en) | 2012-12-07 | 2019-04-30 | The Regents Of The University Of California | Factor VIII mutation repair and tolerance induction |
| US9914764B2 (en) | 2013-03-15 | 2018-03-13 | Bayer Healthcare, Llc | Variant factor VIII polypeptides and methods of their production and use |
| US20160038575A1 (en) * | 2013-03-15 | 2016-02-11 | Haplomics, Inc. | Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a |
| HK1220376A1 (zh) | 2013-03-15 | 2017-05-05 | Angelica Therapeutics, Inc. | 修饰的毒素 |
| US11441122B2 (en) | 2017-10-05 | 2022-09-13 | Epivax Inc. | Regulatory T cell epitopes |
| EP3775194B1 (de) * | 2018-04-12 | 2023-06-28 | Biotest AG | De-immunisiertes faktor-viii-molekül und pharmazeutische zusammensetzungen damit |
| AU2019306194A1 (en) * | 2018-07-16 | 2021-02-04 | Baxalta GmbH | Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180371B1 (en) * | 1996-06-26 | 2001-01-30 | Emory University | Modified factor VIII |
| US20020068303A1 (en) * | 1994-07-14 | 2002-06-06 | Ruth Laub | Antigenic polypeptide sequences of factor VIII, and fragments and/or epitopes of these sequences |
| BE1008491A3 (fr) * | 1994-07-14 | 1996-05-07 | Croix Rouge De Belgique Depart | Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci. |
| WO1997003195A1 (en) * | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
| AU736549B2 (en) * | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| GB9712892D0 (en) * | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
| US6835550B1 (en) * | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
| US6759216B1 (en) * | 1998-11-06 | 2004-07-06 | Emory University | Glycosylated, low antigenicity low immunogenicity factor VIII |
| JP2002534959A (ja) * | 1998-12-08 | 2002-10-22 | バイオベーション リミテッド | 免疫原性タンパク質の改変方法 |
| WO2002096454A1 (en) * | 2001-05-31 | 2002-12-05 | D. Collen Research Foundation Vzw | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
-
2003
- 2003-04-17 CA CA002482926A patent/CA2482926A1/en not_active Abandoned
- 2003-04-17 PL PL03371278A patent/PL371278A1/xx unknown
- 2003-04-17 ES ES03746308T patent/ES2319758T3/es not_active Expired - Lifetime
- 2003-04-17 KR KR10-2004-7016714A patent/KR20040103970A/ko not_active Withdrawn
- 2003-04-17 EP EP03746308A patent/EP1495052B9/de not_active Expired - Lifetime
- 2003-04-17 MX MXPA04010061A patent/MXPA04010061A/es not_active Application Discontinuation
- 2003-04-17 BR BR0308860-0A patent/BR0308860A/pt not_active Application Discontinuation
- 2003-04-17 CN CNA038087014A patent/CN1646564A/zh active Pending
- 2003-04-17 US US10/511,559 patent/US20050256304A1/en not_active Abandoned
- 2003-04-17 DE DE60324406T patent/DE60324406D1/de not_active Expired - Fee Related
- 2003-04-17 WO PCT/EP2003/004063 patent/WO2003087161A1/en not_active Ceased
- 2003-04-17 AU AU2003232482A patent/AU2003232482A1/en not_active Abandoned
- 2003-04-17 AT AT03746308T patent/ATE412671T1/de not_active IP Right Cessation
- 2003-04-17 RU RU2004133761/13A patent/RU2004133761A/ru not_active Application Discontinuation
- 2003-04-17 JP JP2003584116A patent/JP2005538694A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1495052B9 (de) | 2009-12-16 |
| PL371278A1 (en) | 2005-06-13 |
| KR20040103970A (ko) | 2004-12-09 |
| EP1495052A1 (de) | 2005-01-12 |
| AU2003232482A1 (en) | 2003-10-27 |
| CA2482926A1 (en) | 2003-10-23 |
| ES2319758T3 (es) | 2009-05-12 |
| EP1495052B1 (de) | 2008-10-29 |
| MXPA04010061A (es) | 2004-12-13 |
| WO2003087161A1 (en) | 2003-10-23 |
| JP2005538694A (ja) | 2005-12-22 |
| BR0308860A (pt) | 2005-01-04 |
| RU2004133761A (ru) | 2005-07-10 |
| US20050256304A1 (en) | 2005-11-17 |
| DE60324406D1 (de) | 2008-12-11 |
| CN1646564A (zh) | 2005-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60324406D1 (de) | Modifizierter faktor viii | |
| MXPA04001982A (es) | Factor ix modificado. | |
| AU2002302255A1 (en) | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases | |
| MXPA02005576A (es) | Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides. | |
| AU2003242305A1 (en) | Hla-a24-restricted cancer antigen peptide | |
| CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
| MXPA04004417A (es) | Anticuerpo anti-tnf alfa modificado. | |
| CN101687022A8 (zh) | Prame衍生的肽以及包括该肽的免疫原组合物 | |
| PL2087904T3 (pl) | Zastosowanie terapeutyczne peptydów pochodzących z białek BcL-XL u pacjentów z rakiem | |
| PL366826A1 (en) | Reducing the immunogenicity of fusion proteins | |
| DK1329458T5 (da) | Peptider som sænker blodglucoseniveauer | |
| EA201070681A1 (ru) | Пептиды fviii и их применение для индукции толерантности у больных гемофилией | |
| DE60322225D1 (en) | T-zellen-epitope in erythropoietin | |
| HUP0400703A2 (hu) | Csökkentett immunogenitású módosított eritropoietin (EPO) | |
| DE69508382D1 (de) | Peptomere mit erhöhter immunogenizität | |
| MXPA04001976A (es) | Hormona de crecimiento humano modificada. | |
| EP1499349A4 (de) | Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens | |
| BR0311308A (pt) | Briodina 1 modificada com imunogenicidade reduzida | |
| MXPA04004970A (es) | Epitopos de linfocitos t en carboxipeptidasa g2. | |
| ATE435660T1 (de) | Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen | |
| WO2003025014A3 (fr) | Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes | |
| BR112013009276A2 (pt) | peptídeos de c18orf54 e vacinas incluindo os mesmos | |
| WO2003040176A3 (fr) | Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |